Nutiani: Fueling the Next Generation of Probiotic Formulas

The human body contains trillions of microorganisms — outnumbering human cells by 10 to 1(1). The body is their host and they interact with our human cells in ways that scientists and formulators have only recently begun to fully comprehend.

Fortunately, there is a powerful foundation of research behind Nutiani HN001™ and Nutiani HN019™ supporting structure-function benefits in the areas of immunity, gut health, normal digestion, bone health, healthy mood, skin health, certain markers of inflammation, and more.*

The proprietary manufacturing methods used to produce both Nutiani HN001 and Nutiani HN019 yield robust probiotics with excellent shelf-life stability and reduced die-off rate. Formulators can have confidence that their products are delivering on dosage and benefit claims while minimizing waste and improving cost-in-use.

Nutiani Status


Nutiani HN001™

Supported by 40 human clinical trials, New Zealand-sourced Nutiani HN001™ (Lactocaseibacillus rhamnosus) is one of the most extensively researched probiotics in humans.

Nutiani HN001— which is manufactured using a proprietary method that increases stability and helps retain viability—supports a range of benefits to the microbiome including immunity, women’s health, skin health, and mood support.*

Mechanism of Action
It's a strain of L. rhamnosus that:

  • Works to improve digestive health by reducing gut discomfort and constipation as well as potentially reducing the risk of allergens.*
  • Supports healthy immunity (2,3).*
  • May reduce a specific type of inflammation associated with increased cytokine interleukin 6 levels.*
  • Can also improve magnesium and calcium retention, which supports bone mineral density.*
  • May support healthy mood in women (4).*

Click to Request Clinical Research Summaries

Nutiani HN001 is a non-GMO ingredient in freeze-dried powder form with a minimum cell count of 550B CFU/g.


Nutiani HN019™

Supported by over 34 human clinical trials, Nutiani HN019™ is another extensively researched probiotic strain in humans.

Nutiani HN019 supports a range of benefit claims in digestive health and immunity and is known for its demonstrated ability to tolerate the acidic stomach environment and survive passage through the human intestinal tract.*

Clinical data suggests Nutiani HN019 may influence colonic mobility and increased gut transit speed in persons with less frequent bowel movements. It has also been shown to improve gut integrity, barrier function and immunity support.*

Backed by 35+ human clinical studies that support gut integrity and barrier functions in both young and older populations, Nutiani HN019 (Bifidobacterium lactis) is also manufactured using a proprietary method that increases stability and helps retain viability.

Mechanism of Action
It’s a strain of B. lactis that:

  • May enhance immunity (6,7).*
  • Promotes bowel movement by decreasing intestinal transit time (8).*
  • Can improve the gut microbiota (9).*
  • Can enhance the body’s natural protection against constipation (10).*
  • Could reduce specific inflammation.*
  • May improve the availability of iron in the body.*

Click to Request Clinical Research Summaries


References

1.National Institutes of Health. NIH Human Microbiome Project defines normal bacterial makeup of the body. June 13, 2012 [news release].

2.Gill HS, Rutherfurd KJ, Cross ML. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. J Clin Immunol. 2001;21(4):264–271.

3.Gill HS and Rutherford KJ. Probiotic supplementation to enhance natural immunity in the elderly: effects of a newly characterized immunostimulatory strain Lactobacillus rhamnosus HN001 (DR20™) on leucocyte phagocytosis. Nutrition Research. 2001;21(1-2):183–189.

4.Slykerman RF, Hood F, Wickens K, et al. Probiotic in Pregnancy Study Group. Effect of Lactobacillus rhamnosus HN001 in pregnancy on postpartum symptoms of depression and anxiety: A randomized double-blind placebo-controlled trial. EBioMedicine. 2017;24:159–165.

5. Wickens K, Stanley TV, Mitchell EA, et al. Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization? Clin Exp Allergy. 2013;43(9):1048–1057.

6.Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr. 2000;54(3):263–267.

7. Chiang B., Sheih Y, Wang L, et al. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): Optimization and definition of cellular immune responses. Eur J Clin Nutr. 2000;54:849–855.

8. Waller PA, Gopal PK, Leyer GJ, et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 2011;46(9):1057–1064.

9.Ahmed M, Prasad J, Gill H, et al. Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects. J Nutr Health Aging. 2007;11(1):26–31.

10.Ibarra A, Latreille-Barbier M, Donazzolo Y, et al. Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. 2018;9(3):236–251.